article thumbnail

PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE UNTIL MARCH 2027

The Pharma Data

RE47,739 (‘739) by more than four years until March 5, 2027. Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate extends the term of U.S. of IBRANCE-treated patients had ILD/pneumonitis of any grade, 0.1%

article thumbnail

How Many Clinical Trials Are Run by CROs?

Vial

Contract research organizations (CROs) are an integral partner of the drug development process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. That is, how many clinical trials are actually managed by these organizations?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article EMA Thank You Updated EUDAMED roadmap projects mandatory use of some processes as early as December 2025

Agency IQ

Ultimately, this module will interact with CTIS , the drug clinical trial information system. The independent auditing schedule showed publication of full functionality in mid-2027. Another notable challenge has been development of the clinical investigation and performance study module (CI/PS).

article thumbnail

When Worlds Collide: The Theory of Real-World Evidence Meets Reality

FDA Law Blog: Biosimilars

FDA has even gone so far as to maintain that the “real-life clinical performance of a medical product might be more clearly demonstrated through RWD/RWE because a controlled clinical trial often cannot evaluate all applications of a product in clinical practice across the full range of potential users.”

FDA 109
article thumbnail

Wearables, Sensors, and Apps Part 1 – Updates on FDA’s PDUFA VII Goals for the Use of Digital Health Technologies in Drug and Biological Product Development

FDA Law Blog: Biosimilars

DHTs have been used in clinical trials for decades in the context of measurements made when participants visit clinical trial sites. DHTs have been used in clinical trials for decades in the context of measurements made when participants visit clinical trial sites.

article thumbnail

The Biotech Startup Contraction Continues… And That’s A Good Thing

LifeSciVC

While it may help shake out some incremental advances for the therapeutic armamentarium, this dynamic also clearly creates inefficiencies and waste – both in terms of capital deployment, but also for patients’ engagement and clinical trial activity. Fewer startups over time should ameliorate this crowding dynamic to some extent.

DNA 110
article thumbnail

Improving Study Activation Time for Gene Therapy Research

Advarra

between 2020-2027. However, simply having an IBC is much different than actively managing the IBC review process as part of an overall strategy to streamline trial activation. Of the respondents who have an IBC at their organization, 54% indicated the review process for human trials exceeds 30 days.